Wrexham-based Aparito, the developer of the Atom5™ software platform and app that efficiently addresses several problems that traditionally plague clinical trials, i.e. poor patient experience and high costs, has been sold to a large US pharmaceutical company.

GRAY is delighted to have played a part in Aparito’s journey, having built the financial forecast model for Aparito's Seed funding round and ongoing operational use.

‍